_id
6911c6bbccc777a4e85d6596
Ticker
HOPHF
Name
Hemogenyx Pharmaceuticals Plc
Exchange
PINK
Address
6 Heddon Street, London, United Kingdom, W1B 4BT
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://hemogenyx.com
Description
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
Last Close
2.33
Volume
-
Current Price
2.33
Change
0
Last Updated
2026-01-04T14:37:56.037Z
Image
data:image/webp;base64,UklGRhAIAABXRUJQVlA4WAoAAAAQAAAAPwAAPwAAQUxQSE0FAAANuS5E9D9EVmvbeiZJ6tFaa/9NGjZUa60liEgRmQ4c9NDPO3k5EOSyR34DJnkY8KPH7ojgVQZE83/E50Dyah4OfOTjnQZ08xgSMQET8EZu+X30IZ/yNV/wJ9/0Dd/xWx82/dUHfMwXcdf9F7/3I18HfAT320K+R+L9lLIs614IZBljWXfPleU/k6gsI+6+zB85sj6ohoq8BzjXYFZrafiDe2C7L61Xq5FK7r5lo6yUEvd7IFxjlvwb3Nvi+lM5ekeF0B25aTWXnWUs7q0RLu5pBFkqFboDQq7K7KFqV2THNECIpgxbZd0SchWF3WeudGIZGaEypEhxy+WGK0XSr0oQBQKaJHCWQbeiiXQ4otnLvM0mmyh7gw5ZDgmgiox0CW2Zmta1O1W476sVsG9qKhGVU2tuWjOwaoOWsp3VsICa3ZyhVkl1zQB9ItWU1VGbXKTTeGw0ChkTYqvTQJlKVLnxST/zUdhgwGE7uitLG8MIZSXURv8dRTaeTljt6NhQLJkLm7EXqZgwiGl5zoZqVTq1ZZEFXN7+G21qwh+n9dcuTrYfhqkxlQWdB7Wp3CwTydiIaPqEE5yjmKrlY4tQEofHLf3smpgkl88Y205RKaEt2Wv9nJ/iVwZ1bCrS5dY1Tg8br35oKLEoGfa4L6Qr2xyqDTvG8vBpP7FMTDidZFTNNZ72moEvexPHHIgOL6YkJYRKjo0M9/WXaoynAuyetieqNUyTf2FP5jqMgQusuJpKrXTa0j1Cw+1YkUq722q0VvJRsZ7SEfQygG2tjJJUEtsLIUoi3TNNlUpNyLZoWUSL2pjUU5KHiLZuaXO20TRlsC7dGMiSDM5Mzx3JKTafsbBqyNlzyxGI9mz1WA7vMB1H0UqqsrsZ00r0UNsCY8nKUiXpLZvPb62R5PJzp3h8tBoaWWUZsp5zPmVOV2gRZUxynccFUmFoLuFSVGYY4PLYUJWvQAPlwg0vqcAez28zj1ZklwWx4T3Zhuuqids8KEuiCajJmQE27WkBB1XNcdXtRkjBqLlVRrJmdCWMeXRy0WhD592kY0TlVEdWKcCyo/zivcuy4EKN3ZbKZZsoR3dqpFdhDnNmSiJ2hIydVpX74vHe2SvOXEeVoFVqRzaEEk2ujJnD477O4XBEUxOqdUcj8HD0VyuRe8hFqkEztsBrsuNi62H/mvTwfJomzY8GsKRk1zU19f0yza9Xz30qT/TxOFiXHhkp9eOOmIeW49uXF69PPH+GGquHnp59PlihxF6G2y7kclXX3mlQpTKfMFL1SqOiN3aaC70bHR90bGVcXvcnLXuOr36sWeVip7WWs1Of905ojCFD9iYS4uXzxSXJu1CtIiAPn3WghiwluUfH6vBCJVWyy7FXWIAvgyrXSmU4df5/nF/OQqOzQ7nTySkSDq/KWVlIFU5eTnpLEwS7THVF6PDvF6fLq1Khyko5Q+HearRKZ+334RrXky1AeHVn+tc4VjWAQgoyPMdAY6oIsrwyfD0jto6TTIqiUKbSVEmqAoxMpU116wbiyuNeqmpSVkSkNTRieXIdYx2nmiuViFFcX+hhyv27F8Ibk5LMfn5XE0N+tk2DzlGSrUI3AKajXyjjNCSpVKHo61kPbi1nzmxWg2aMLN3IDlCpKBUyKacTI6mzrVaFEjU3bnwZrPUUDY0EY0dMczVOXLNWY0Qh+yaZdmulTAuwHdb0rGeuveLsobnN1ZebsF/a3OaKLngCp5M2e52uZTKWXjGeWNqN0mmXKgA5IYXwnusbwMIK32jMNLoygTCmLKh2PUk19dLlTW6uAOUiA3QwKoD5BlwbAFZQOCCcAgAAUA8AnQEqQABAAD61Sp5KJyQioa4W3VDgFolsAMHJrtdeGH4fzGLU2swq1gz1ObZ/zMfr1+nPuueiD9ZOBj9AD9pPTQ/bz4Rf3I9JUNHraOUZG9T0pcACfKJhD/CaKVzrYFUqQiThoiP2iPKbRjRFN1LjNIRXOX6szdGDEIq8OCMjHuQA/vz4RTGO7Bo/nZ98IFuVnAijVnpXN3xap3t8Bftf+nrf5kjP+kTjRxSvP/K2O65HlwdQ48wWn/2OSK/FnCyaEQ+2cb46/QnR7YaZVaqsn0Z1xo+14XqK97qfLfAx0q7amdwZw6T+JXlJOV9NOAf8kJWIh36NZlN7yWNQDfJEjRQ7hG7PeFF2di/oIk5PTuThp/4NTyjTumh1GZq07r5bctHoRNxb3w7bQL5K45XYcJLLkMD6muaYdnF6GB4PQIudSXDcYix+fHB8NkFY32bq6x8Jzd5m+otD70Rki5I3KruBKLXVe8S8LsCO+0zp7ufMnapaxH9XdYflDNchoqtMnZiY5hyzyLn8xlDHl963gDbzUa9Hys4jtftbzfpJ2s/4GD9GkOBwSG2c6fwhK0SJfCEhyoS54G9TafwGsuyVX1W+wsgGxVn8D6JoXpmlGhkaw8YVTiuBEfnwoEnjJCcyotuEMKjexONB3tN5YW+U28PqsN9G7KiWJfpbhgo2o1Hu/X2TLMYdoL3iSkPvQ+D/Ej1zBymn1XkAZTO2WWo2tborqFyQBKRZcPvbrwtngK78Oe7M2De2zecsWa88qcAASVFbHp9ecRrXq2Wg2ffSLezXXAvaPz/eXGQWDZxtJdvqzM674Egyz5cWAl++V7XXAza32VLEYzYr2nr07WCvVmn7SZqe+GrTZlm/yUr6SZfry+TlHRIyAAA=
Ipo Date
-
Market Cap
14076124
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
-
Cost Of Revenue
430761
Gross Profit
-430761
Operating Expenses
3108420
Operating Income
-3539181
Interest Expense
164583
Pretax Income
-6872806
Net Income
-6869725
Eps
-1.9428405862353142
Dividends Per Share
-
Shares Outstanding
6041255
Income Tax Expense
-
EBITDA
-6277454
Operating Margin
-
Total Other Income Expense Net
-3333625
Cash
311250
Short Term Investments
-
Receivables
470988
Inventories
-
Total Current Assets
782239
Property Plant Equipment
3010068
Total Assets
4257409
Payables
909279
Short Term Debt
567673
Long Term Debt
-
Total Liabilities
5007522
Equity
-686601
Bs_currency_symbol
GBP
Depreciation
430761
Change In Working Capital
800000
Cash From Operations
-5193581
Capital Expenditures
5377
Cash From Investing
356984
Cash From Financing
2295412
Net Change In Cash
111994
Cf_currency_symbol
-
PE
-
PB
-11.999238189283151
ROE
1000.5410711606887
ROA
-161.3592915315395
FCF
-5198958
Fcf Percent
-
Piotroski FScore
1
Health Score
39
Deep Value Investing Score
0.5
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
4.8
Garp Investing Score
2
Growth Investing Score
2
Momentum Investing Score
4.5
Net Net Investing Score
0.5
Quality Investing Score
2.5
Value Investing Score
2.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
-
Quarters > 0 > income Statement > cost Of Revenue
430761
Quarters > 0 > income Statement > gross Profit
-430761
Quarters > 0 > income Statement > operating Expenses
3108420
Quarters > 0 > income Statement > operating Income
-3539181
Quarters > 0 > income Statement > interest Expense
164583
Quarters > 0 > income Statement > pretax Income
-6872806
Quarters > 0 > income Statement > net Income
-6869725
Quarters > 0 > income Statement > eps
-1.9428405862353142
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
3535918
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-6277454
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-3333625
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
311250
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
470988
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
782239
Quarters > 0 > balance Sheet > property Plant Equipment
3010068
Quarters > 0 > balance Sheet > total Assets
4257409
Quarters > 0 > balance Sheet > payables
909279
Quarters > 0 > balance Sheet > short Term Debt
567673
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
5007522
Quarters > 0 > balance Sheet > equity
-686601
Quarters > 0 > balance Sheet > currency_symbol
GBP
Quarters > 0 > cash Flow > net Income
-6869725
Quarters > 0 > cash Flow > depreciation
430761
Quarters > 0 > cash Flow > change In Working Capital
800000
Quarters > 0 > cash Flow > cash From Operations
-5193581
Quarters > 0 > cash Flow > capital Expenditures
5377
Quarters > 0 > cash Flow > cash From Investing
356984
Quarters > 0 > cash Flow > cash From Financing
2295412
Quarters > 0 > cash Flow > net Change In Cash
111994
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-1.9428405862353142
Quarters > 0 > ratios > PB
-11.999238189283151
Quarters > 0 > ratios > ROE
1000.5410711606887
Quarters > 0 > ratios > ROA
-161.3592915315395
Quarters > 0 > ratios > FCF
-5198958
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
39
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
397349
Quarters > 1 > income Statement > gross Profit
-397349
Quarters > 1 > income Statement > operating Expenses
2963038
Quarters > 1 > income Statement > operating Income
-3360388
Quarters > 1 > income Statement > interest Expense
162346
Quarters > 1 > income Statement > pretax Income
-3515433
Quarters > 1 > income Statement > net Income
-5616368
Quarters > 1 > income Statement > eps
-1.6025977731742254
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
3504540
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-2455485
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-155045
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
159265
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
3768
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
839048
Quarters > 1 > balance Sheet > property Plant Equipment
2727221
Quarters > 1 > balance Sheet > total Assets
4211560
Quarters > 1 > balance Sheet > payables
683284
Quarters > 1 > balance Sheet > short Term Debt
953730
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
3358066
Quarters > 1 > balance Sheet > equity
897514
Quarters > 1 > balance Sheet > currency_symbol
GBP
Quarters > 1 > cash Flow > net Income
-2806349
Quarters > 1 > cash Flow > depreciation
317600
Quarters > 1 > cash Flow > change In Working Capital
157578
Quarters > 1 > cash Flow > cash From Operations
-2231215
Quarters > 1 > cash Flow > capital Expenditures
16623
Quarters > 1 > cash Flow > cash From Investing
-31147
Quarters > 1 > cash Flow > cash From Financing
293802
Quarters > 1 > cash Flow > net Change In Cash
-1877687
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-1.6025977731742254
Quarters > 1 > ratios > PB
9.097995351604544
Quarters > 1 > ratios > ROE
-625.7694030399525
Quarters > 1 > ratios > ROA
-133.3560011017295
Quarters > 1 > ratios > FCF
-2247838
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
17
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
-
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
2691.14
Quarters > 2 > income Statement > operating Income
-2691.14
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-2815.6
Quarters > 2 > income Statement > net Income
-2812.83
Quarters > 2 > income Statement > eps
-0.9170527345341919
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
3067.25
Quarters > 2 > income Statement > income Tax Expense
-1.39
Quarters > 2 > income Statement > EBITDA
-2691023.2
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-124.46
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
1642762
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
827867
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
2470629
Quarters > 2 > balance Sheet > property Plant Equipment
3006965
Quarters > 2 > balance Sheet > total Assets
6116262
Quarters > 2 > balance Sheet > payables
308660
Quarters > 2 > balance Sheet > short Term Debt
255604
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
3092852
Quarters > 2 > balance Sheet > equity
3063905
Quarters > 2 > balance Sheet > currency_symbol
GBP
Quarters > 2 > cash Flow > net Income
-2812.83
Quarters > 2 > cash Flow > depreciation
321.69
Quarters > 2 > cash Flow > change In Working Capital
98.66
Quarters > 2 > cash Flow > cash From Operations
-2350.82
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
17.33
Quarters > 2 > cash Flow > cash From Financing
2842.62
Quarters > 2 > cash Flow > net Change In Cash
1642.76
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.9170527345341919
Quarters > 2 > ratios > PB
0.0023325437635958036
Quarters > 2 > ratios > ROE
-0.09180539213846382
Quarters > 2 > ratios > ROA
-0.04598936409198952
Quarters > 2 > ratios > FCF
-2350.82
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
32
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
1345.57
Quarters > 3 > income Statement > operating Income
-1345.57
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-1407.8
Quarters > 3 > income Statement > net Income
-1406.42
Quarters > 3 > income Statement > eps
-0.0000011463199934795013
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
1226900000
Quarters > 3 > income Statement > income Tax Expense
-1.39
Quarters > 3 > income Statement > EBITDA
-1287168
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-1406456.43
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
1642762
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
2470629
Quarters > 3 > balance Sheet > property Plant Equipment
3006965
Quarters > 3 > balance Sheet > total Assets
6116262
Quarters > 3 > balance Sheet > payables
308660
Quarters > 3 > balance Sheet > short Term Debt
255604
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
3092852
Quarters > 3 > balance Sheet > equity
3063905
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-1406.42
Quarters > 3 > cash Flow > depreciation
160.84
Quarters > 3 > cash Flow > change In Working Capital
49.33
Quarters > 3 > cash Flow > cash From Operations
-1175.41
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
1421.31
Quarters > 3 > cash Flow > net Change In Cash
197.58
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.0000011463199934795013
Quarters > 3 > ratios > PB
933.0175054383215
Quarters > 3 > ratios > ROE
-0.04590285925967026
Quarters > 3 > ratios > ROA
-0.022994763795272342
Quarters > 3 > ratios > FCF
-1175.41
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
25
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
799809
Annuals > 0 > income Statement > gross Profit
-799809
Annuals > 0 > income Statement > operating Expenses
6364857
Annuals > 0 > income Statement > operating Income
-7164666
Annuals > 0 > income Statement > interest Expense
339742
Annuals > 0 > income Statement > pretax Income
-7038035
Annuals > 0 > income Statement > net Income
-5619181
Annuals > 0 > income Statement > eps
-1.7020440530182215
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
3301431
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-5146509
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
126631
Annuals > 0 > income Statement > currency_symbol
GBP
Annuals > 0 > balance Sheet > cash
159265
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
3768
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
839048
Annuals > 0 > balance Sheet > property Plant Equipment
2727221
Annuals > 0 > balance Sheet > total Assets
4211560
Annuals > 0 > balance Sheet > payables
683284
Annuals > 0 > balance Sheet > short Term Debt
953730
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
3358066
Annuals > 0 > balance Sheet > equity
897514
Annuals > 0 > balance Sheet > currency_symbol
GBP
Annuals > 0 > cash Flow > net Income
-5625478
Annuals > 0 > cash Flow > depreciation
639285
Annuals > 0 > cash Flow > change In Working Capital
256243
Annuals > 0 > cash Flow > cash From Operations
-4140059
Annuals > 0 > cash Flow > capital Expenditures
13285
Annuals > 0 > cash Flow > cash From Investing
-1732
Annuals > 0 > cash Flow > cash From Financing
3077453
Annuals > 0 > cash Flow > net Change In Cash
-1088336
Annuals > 0 > cash Flow > currency_symbol
GBP
Annuals > 0 > ratios > PE
-1.7020440530182215
Annuals > 0 > ratios > PB
8.570712245157178
Annuals > 0 > ratios > ROE
-626.0828243347736
Annuals > 0 > ratios > ROA
-133.422793454207
Annuals > 0 > ratios > FCF
-4153344
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
8
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
645681
Annuals > 1 > income Statement > gross Profit
-645681
Annuals > 1 > income Statement > operating Expenses
6465.85
Annuals > 1 > income Statement > operating Income
-6465.85
Annuals > 1 > income Statement > interest Expense
230.65
Annuals > 1 > income Statement > pretax Income
-6696.49
Annuals > 1 > income Statement > net Income
-6690.68
Annuals > 1 > income Statement > eps
-2.370194555837384
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
2822.84
Annuals > 1 > income Statement > income Tax Expense
-5816
Annuals > 1 > income Statement > EBITDA
-5333.15
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-230.65
Annuals > 1 > income Statement > currency_symbol
GBP
Annuals > 1 > balance Sheet > cash
1247601
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
1074
Annuals > 1 > balance Sheet > inventories
-1074
Annuals > 1 > balance Sheet > total Current Assets
2169614
Annuals > 1 > balance Sheet > property Plant Equipment
3312438
Annuals > 1 > balance Sheet > total Assets
6105893
Annuals > 1 > balance Sheet > payables
301707
Annuals > 1 > balance Sheet > short Term Debt
273084
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
3324887
Annuals > 1 > balance Sheet > equity
2818729
Annuals > 1 > balance Sheet > currency_symbol
GBP
Annuals > 1 > cash Flow > net Income
-6696493
Annuals > 1 > cash Flow > depreciation
645681
Annuals > 1 > cash Flow > change In Working Capital
-833596
Annuals > 1 > cash Flow > cash From Operations
-6105570
Annuals > 1 > cash Flow > capital Expenditures
117285
Annuals > 1 > cash Flow > cash From Investing
-31941
Annuals > 1 > cash Flow > cash From Financing
4449311
Annuals > 1 > cash Flow > net Change In Cash
-1285157
Annuals > 1 > cash Flow > currency_symbol
GBP
Annuals > 1 > ratios > PE
-2.370194555837384
Annuals > 1 > ratios > PB
0.002333398208909051
Annuals > 1 > ratios > ROE
-0.23736513868484696
Annuals > 1 > ratios > ROA
-0.10957741971567468
Annuals > 1 > ratios > FCF
-6222855
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
23
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
2599762
Annuals > 2 > income Statement > gross Profit
-2599762
Annuals > 2 > income Statement > operating Expenses
2930725
Annuals > 2 > income Statement > operating Income
3997548
Annuals > 2 > income Statement > interest Expense
33
Annuals > 2 > income Statement > pretax Income
-3986982
Annuals > 2 > income Statement > net Income
-3979314
Annuals > 2 > income Statement > eps
-1624.627557290242
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
2449.37
Annuals > 2 > income Statement > income Tax Expense
361203
Annuals > 2 > income Statement > EBITDA
-5440520
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
10566
Annuals > 2 > income Statement > currency_symbol
GBP
Annuals > 2 > balance Sheet > cash
2532758
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
146
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
2594782
Annuals > 2 > balance Sheet > property Plant Equipment
3915513
Annuals > 2 > balance Sheet > total Assets
7092609
Annuals > 2 > balance Sheet > payables
374342
Annuals > 2 > balance Sheet > short Term Debt
322157
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
3849089
Annuals > 2 > balance Sheet > equity
3275428
Annuals > 2 > balance Sheet > currency_symbol
GBP
Annuals > 2 > cash Flow > net Income
-3986982
Annuals > 2 > cash Flow > depreciation
195246
Annuals > 2 > cash Flow > change In Working Capital
242590
Annuals > 2 > cash Flow > cash From Operations
-2910604
Annuals > 2 > cash Flow > capital Expenditures
428945
Annuals > 2 > cash Flow > cash From Investing
-420254
Annuals > 2 > cash Flow > cash From Financing
-110144
Annuals > 2 > cash Flow > net Change In Cash
-4308211
Annuals > 2 > cash Flow > currency_symbol
GBP
Annuals > 2 > ratios > PE
-1624.627557290242
Annuals > 2 > ratios > PB
0.0017423775152438092
Annuals > 2 > ratios > ROE
-121.48989383982796
Annuals > 2 > ratios > ROA
-56.10508065508757
Annuals > 2 > ratios > FCF
-3339549
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
23
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
283647
Annuals > 3 > income Statement > gross Profit
-283647
Annuals > 3 > income Statement > operating Expenses
2546975
Annuals > 3 > income Statement > operating Income
-2702754
Annuals > 3 > income Statement > interest Expense
2595389
Annuals > 3 > income Statement > pretax Income
-5108310
Annuals > 3 > income Statement > net Income
-5099228
Annuals > 3 > income Statement > eps
-2635.423385429587
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
1934.88
Annuals > 3 > income Statement > income Tax Expense
2411178
Annuals > 3 > income Statement > EBITDA
-2576414
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-2405556
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
6840969
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
1386
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
7139189
Annuals > 3 > balance Sheet > property Plant Equipment
797129
Annuals > 3 > balance Sheet > total Assets
8520410
Annuals > 3 > balance Sheet > payables
295829
Annuals > 3 > balance Sheet > short Term Debt
10152
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
352841
Annuals > 3 > balance Sheet > equity
8191809
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-5108310
Annuals > 3 > cash Flow > depreciation
126340
Annuals > 3 > cash Flow > change In Working Capital
101387
Annuals > 3 > cash Flow > cash From Operations
-2627298
Annuals > 3 > cash Flow > capital Expenditures
817998
Annuals > 3 > cash Flow > cash From Investing
-938953
Annuals > 3 > cash Flow > cash From Financing
8777640
Annuals > 3 > cash Flow > net Change In Cash
5028670
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-2635.423385429587
Annuals > 3 > ratios > PB
0.000550338807948281
Annuals > 3 > ratios > ROE
-62.24788688310482
Annuals > 3 > ratios > ROA
-59.847213925151486
Annuals > 3 > ratios > FCF
-3445296
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
33
Valuation > metrics > PE
-1.9428405862353142
Valuation > metrics > PB
-11.999238189283151
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
1000.5410711606887
Profitability > metrics > ROA
-878.213052532538
Profitability > final Score
55
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-21.503928109221487
Risk > final Score
-56
Risk > verdict
High
Liquidity > metrics > Current Ratio
0.5296306176504043
Liquidity > metrics > Quick Ratio
0.5296306176504043
Liquidity > final Score
36
Liquidity > verdict
Weak
Prev Valuations > 0
20
Prev Valuations > 1
70
Prev Valuations > 2
20
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
-77
Prev Risks > 1
30
Prev Risks > 2
30
Prev Liquidities > 0
36
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:59:04.728Z
Earnings History > 0 > period
2026-03-31
Earnings History > 0 > report Date
2026-04-27
Earnings History > 0 > date
2026-03-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2021-03-31
Earnings History > 1 > report Date
2021-06-30
Earnings History > 1 > date
2021-03-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
GBP
Earnings History > 1 > eps Actual
-0.0046
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-0.0046
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2020-12-31
Earnings History > 2 > report Date
2021-03-31
Earnings History > 2 > date
2020-12-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
GBP
Earnings History > 2 > eps Actual
-0.0046
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
-0.0046
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2020-09-30
Earnings History > 3 > report Date
2020-12-31
Earnings History > 3 > date
2020-09-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
GBP
Earnings History > 3 > eps Actual
-0.002
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
-0.002
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2020-06-30
Earnings History > 4 > report Date
2020-09-30
Earnings History > 4 > date
2020-06-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
GBP
Earnings History > 4 > eps Actual
-0.0019
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
-0.0019
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2020-03-31
Earnings History > 5 > report Date
2020-06-30
Earnings History > 5 > date
2020-03-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
GBP
Earnings History > 5 > eps Actual
-0.0013
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
-0.0013
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2019-12-31
Earnings History > 6 > report Date
2020-03-31
Earnings History > 6 > date
2019-12-31
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
GBP
Earnings History > 6 > eps Actual
-0.0013
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
-0.0013
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2019-09-30
Earnings History > 7 > report Date
2019-12-31
Earnings History > 7 > date
2019-09-30
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
GBP
Earnings History > 7 > eps Actual
-0.0014
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
-0.0014
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2019-06-30
Earnings History > 8 > report Date
2019-09-30
Earnings History > 8 > date
2019-06-30
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
GBP
Earnings History > 8 > eps Actual
-0.0013
Earnings History > 8 > eps Estimate
0
Earnings History > 8 > eps Difference
-0.0013
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2019-03-31
Earnings History > 9 > report Date
2019-06-30
Earnings History > 9 > date
2019-03-31
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
GBP
Earnings History > 9 > eps Actual
-0.0012
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
-0.0012
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2018-12-31
Earnings History > 10 > report Date
2019-03-31
Earnings History > 10 > date
2018-12-31
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
GBP
Earnings History > 10 > eps Actual
-0.0013
Earnings History > 10 > eps Estimate
0
Earnings History > 10 > eps Difference
-0.0013
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2018-09-30
Earnings History > 11 > report Date
2018-12-31
Earnings History > 11 > date
2018-09-30
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
GBP
Earnings History > 11 > eps Actual
-0.0016
Earnings History > 11 > eps Estimate
0
Earnings History > 11 > eps Difference
-0.0016
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2018-06-30
Earnings History > 12 > report Date
2018-09-30
Earnings History > 12 > date
2018-06-30
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
GBP
Earnings History > 12 > eps Actual
-0.0016
Earnings History > 12 > eps Estimate
0
Earnings History > 12 > eps Difference
-0.0016
Earnings History > 12 > surprise Percent
-
Earnings History > 13 > period
2018-03-31
Earnings History > 13 > report Date
2018-06-30
Earnings History > 13 > date
2018-03-31
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
GBP
Earnings History > 13 > eps Actual
-0.0012
Earnings History > 13 > eps Estimate
0
Earnings History > 13 > eps Difference
-0.0012
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2017-12-31
Earnings History > 14 > report Date
2018-03-31
Earnings History > 14 > date
2017-12-31
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
GBP
Earnings History > 14 > eps Actual
-0.0013
Earnings History > 14 > eps Estimate
0
Earnings History > 14 > eps Difference
-0.0013
Earnings History > 14 > surprise Percent
-
Earnings History > 15 > period
2017-09-30
Earnings History > 15 > report Date
2017-12-31
Earnings History > 15 > date
2017-09-30
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
GBP
Earnings History > 15 > eps Actual
-0.0051
Earnings History > 15 > eps Estimate
0
Earnings History > 15 > eps Difference
-0.0051
Earnings History > 15 > surprise Percent
-
Earnings History > 16 > period
2017-06-30
Earnings History > 16 > report Date
2017-09-30
Earnings History > 16 > date
2017-06-30
Earnings History > 16 > before After Market
-
Earnings History > 16 > currency
GBP
Earnings History > 16 > eps Actual
-0.0051
Earnings History > 16 > eps Estimate
0
Earnings History > 16 > eps Difference
-0.0051
Earnings History > 16 > surprise Percent
-
Earnings History > 17 > period
2017-03-31
Earnings History > 17 > report Date
2017-06-30
Earnings History > 17 > date
2017-03-31
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
GBP
Earnings History > 17 > eps Actual
-0.0004
Earnings History > 17 > eps Estimate
0
Earnings History > 17 > eps Difference
-0.0004
Earnings History > 17 > surprise Percent
-
Earnings History > 18 > period
2016-12-31
Earnings History > 18 > report Date
2017-03-31
Earnings History > 18 > date
2016-12-31
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
GBP
Earnings History > 18 > eps Actual
-0.0004
Earnings History > 18 > eps Estimate
0
Earnings History > 18 > eps Difference
-0.0004
Earnings History > 18 > surprise Percent
-
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ALondon biotech lines up Jan. 6 listing for fresh batch of shares Stock Titan
Read more →Biotech Hemogenyx adds new shares, reshaping who holds voting power Stock Titan
Read more →Showing 2 of 8
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
* Institutions hold a combined 0.00% of the total shares of Hemogenyx Pharmaceuticals Plc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2026-03-31
EPS Estimate
—
Date
2021-03-31
EPS Actual
-0.0046
EPS Estimate
0
EPS Difference
-0.0046
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.